BCOP Self-Study
These modules focus on literature published within the last two years. Participants will learn about new developments and cutting-edge findings through case-based discussions that help you apply the information presented.
Self-Study 2025 Release II is now available - it contains 11 ACPE and BCOP CEs total.
Learning Opportunities
-
Bundle
Self-Study 2025 Release II Bundle
On-demand The 2025 BCOP Self-Study Bundle Release II offers 11 BCOP CE hours and ACPE CE hours. Learn more -
Individual
Self-Study 2025 Release II: Review of CNS Prophylaxis in Hematologic Malignancies
On-demand At the end of this self-study course, you will have the tools to administer preventative CNS-directed therapy that balances efficacy and toxicity with the patient's overall goals of care. Learn more -
Individual
Self-Study 2025 Release II: Gene Therapy Advances in Hemophilia, Sickle Cell Disease, and Beta-Thalassemia
On-demand In this module, we will explore the different mechanisms of action of available agents and their varied impact on target diseases. Readers will also consider the challenges to incorporating gene therapies into routine care of individuals with hemophilia, sickle cell disease, and beta-thalassemia. Learn more -
Individual
Self-Study 2025 Release II: The Four Body Problem: Four Drug Regimens in Newly Diagnosed Multiple Myeloma
On-demand This module will review the safety and efficacy of four-drug regimens for the treatment of newly diagnosed multiple myeloma. Learn more -
Individual
Self-Study 2025 Release II: Updates in the Treatment of Hormone Receptor-Positive (HR+) Metastatic Breast Cancer
On-demand In this module, participants will evaluate the recent data behind imlunestrant, inavolisib, trastuzumab deruxtecan, and datopotamab deruxtecan and explore the clinical situations in which the utilization of these agents would be appropriate. Learn more -
Individual
Self-Study 2025 Release II: Antibody Drug Conjugates (ADCs) in Solid Tumors
On-demand This module will provide an overview of ADCs structure, including monoclonal antibody, linker, and cytotoxic agent, while also briefly discussing key factors that impact ADC toxicity profiles. Learn more -
Bundle
Self-Study 2025 Release I Bundle
On-demand The 2025 BCOP Self-Study Bundle Release I offers 9.5 BCOP CE hours and ACPE CE hours. Learn more -
Individual
Self-Study 2025 Release I: Treatment of Non-Melanoma Skin Cancers
On-demand The purpose of this course is to review treatment options in the management of non-melanoma skin cancers. This will include a review of the role of immunotherapy and hedgehog pathway inhibitors at different stages, and will include efficacy and safety data, as well as considerations for patient monitoring and toxicity management. Learn more -
Individual
Self-Study 2025 Release I: Anxiety and Depression in Adult Survivors of Cancer
On-demand In this module, participants will explore risk factors and contributors to anxiety and depression in adult persons with cancer, identify scoring tools for assessment, and review data surrounding pharmacologic and non-pharmacologic treatment modalities to address anxiety and depression, including the utilization of cannabis. Learn more -
Individual
Self-Study 2025 Release I: Targeting HER2 in Non-Breast Solid Tumors
On-demand The purpose of this course is to look at the extensive research conducted to look at targeted HER2 therapies in a variety of disease states. Learn more -
Individual
Self-Study 2025 Release I: Germline Genetic Testing in Patients with Cancer
On-demand This session will provide an overview of the prevalence of germline cancer susceptibility mutations in those who are diagnosed with cancer. Learn more -
Individual
Self-Study 2025 Release I: Myeloproliferative Neoplasms - A Focus on JAK Inhibitors in Myelofibrosis
On-demand While research continues beyond JAK inhibitors to new targets, sequencing of these agents in the event of inadequate response or loss of response is an area of ongoing interest. Learn more